

29 August 2008

Proposal regarding quinapril (Accupril) and quinapril with hydrochlorothiazide (Accuretic)

Summary

As a result of a Request for Proposals for the sole supply of quinapril and quinapril with hydrochlorothiazide (dated 18 June 2008), PHARMAC and Pfizer New Zealand Limited have entered into a provisional agreement for the supply of Accupril (quinapril) and Accuretic (quinapril with hydrochlorothiazide). The provisional agreement (subject to consultation and PHARMAC Board approval) would result in:

- price and subsidy reductions for Accupril; and,
- Accupril and Accuretic being the only brands of quinapril and quinapril with hydrochlorothiazide listed in the Pharmaceutical Schedule until 30 June 2011.

Details of the Proposal

Accupril and Accuretic would remain listed in Section B and in Part II of Section H of the Pharmaceutical Schedule at the following reduced prices and subsidies (ex-manufacturer, exclusive of GST) with effect from 1 November 2008:

Pharmaceutical Name (Brand)	Strength and Form	Pack Size	Current price and Subsidy	Proposed price and subsidy
Quinapril (Accupril)	5 mg tab	30	\$2.36	\$1.60
	10 mg tab	30	\$3.26	\$1.75
	20 mg tab	30	\$4.30	\$2.35
Quinapril with hydrochlorothiazide (Accuretic)	10 mg with 12.5 mg tab	30	\$3.37	\$3.37
	20 mg with 12.5 mg tab	30	\$4.57	\$4.57

Accupril and Accuretic would have sole supply status and remain fully funded in Section B of the Pharmaceutical Schedule until 30 June 2011..

This proposal would result in savings in excess of \$2.3 million per year.

Feedback sought

PHARMAC welcomes feedback on this proposal. To provide feedback please submit it in writing by 4 pm on **Friday 12th of September 2008** to:

Stephen Woodruffe
 Therapeutic Group Manager
 PHARMAC
 PO Box 10 254
 Wellington 6143

Email:
stephen.woodruffe@pharmac.govt.nz
 Fax: 04 460 4995

All feedback received before the closing date will be considered by PHARMAC's Board (or Chief Executive acting under delegated authority) prior to making a decision.